Quick Answer
Instil Bio, Inc. reported Research And Development Expense of $39.60 million for the year ending 2023.
- Instil Bio, Inc. showed a decrease of -71.9% in Research And Development Expense from 2022 to 2023.
- This data is from Instil Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 21, 2024.
- XBRL data for this metric is available from 2020 to 2023 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $2.01 million | Q2 2020: $2.24 million | Q3 2020: $4.91 million | Q1 2021: $14.42 million | Q2 2021: $21.19 million | Q3 2021: $29.06 million | Q1 2022: $39.17 million | Q2 2022: $41.50 million | Q3 2022: $39.66 million | Q1 2023: $20.67 million | Q2 2023: $8.46 million | Q3 2023: $8.49 million | Q1 2024: $7.26 million | Q2 2024: $2.92 million.
- Over the full 4 years of available data (2020 to 2023), Instil Bio, Inc.'s Research And Development Expense has grown by 104.2%.
- Historical annual values: Fiscal year 2023: $39.60 million | Fiscal year 2022: $141.06 million | Fiscal year 2021: $107.25 million | Fiscal year 2020: $19.40 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: